Investing Profile

Luke Evnin

VCInvestor
Chairperson at Scleroderma Research Foundation
Photo of Luke Evnin, Scleroderma Research Foundation

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Princeton University Network
293 CONNECTIONS
Accel Partners Network
67 CONNECTIONS
Accel Partners Network
67 CONNECTIONS
Accel Partners Network
67 CONNECTIONS
MPM BioImpact Network
25 CONNECTIONS
cb
$1M - $150.0M
$25.0M
7
CompanyStageDateRound SizeTotal Raised
Umoja Biopharma
Series CJan 2025$100M
Series ANov 2020$53M
$150M
Photys Therapeutics
Series ASep 2022$75M
$75M
Co-investors: David Steinberg (Longwood Fund), Briggs Morrison (MPM Capital)
Werewolf Therapeutics
Series ANov 2019$56M
$130M
Co-investors: Derek DiRocco (RA Capital Management)
Harpoon Therapeutics
Series BMay 2017$45M
$120M
Co-investors: Mark Chin (Jmi Equity)
Oncorus
Series AJul 2016$57M
$77M
Co-investors: Anup Arora (K2 HealthVentures), Cameron Wheeler (Deerfield Management)
Idun Pharmaceuticals
Series BJun 2004$27M
$50M
Co-investors: Dion Madsen (Amplitude Ventures), Tony Evnin (Venrock)
Chairperson Scleroderma Research FoundationPresent
Chairperson Werewolf TherapeuticsPresent
Proprietor Accel PartnersPresent
General Partner Accel PartnersPresent
Co-Founder; Senior Advisor MPM BioImpactPresent
Co-Founder; Senior Advisor Accel PartnersPresent
Princeton University Bachelor’s Degree Molecular Biology
University of California, San Francisco PhD BioChemistry
Sign in with Google →
Sign in with Google →